Kymera STAT6 Phase IIb data and BofA target reviewed
Kymera Therapeutics is advancing its STAT6 program toward Phase III, with Phase IIb atopic dermatitis data due by year-end. The roundup also notes BofA raised its price target to $144.
Kymera Therapeutics is advancing its STAT6 program toward Phase III, with Phase IIb atopic dermatitis data due by year-end. The roundup also notes BofA raised its price target to $144.